With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survival is extended by a new treatment option for metastatic colorectal cancer.

2.

Six breast texture patterns linked to higher risk of invasive cancer

3.

New policy review highlights the importance of health-related quality of life in advanced cancer

4.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

5.

Climate change is expected to increase the number of suicide deaths


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot